# Correction to "Glutamate Receptor Ion Channels: Structure, Regulation, and Function"

In the above article [Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK, Hansen KB, Yuan H, Myers SJ, and Dingledine R (2010) *Pharmacol Rev* **62:**405–496], the enantiomer (−)-ketamine is mislabeled in Table 15 in the first column of the third row. The correct entry should be (+)-ketamine. Please see below for the corrected table.

TABLE 15
$IC_{50}$ values in micromolar for uncompetitive NMDA receptor antagonists

All values were measured in 0 $Mg^{2+}$, unless otherwise indicated. Values for memantine and (±)-ketamine are from Kotermanski and Johnson (2009) with membrane potential held at −66 mV. All remaining values are from Dravid et al. (2007) with membrane potential held at −40 mV.

| Uncompetitive Antagonist | GluN2A | GluN2B | GluN2C | GluN2D |
|---|---|---|---|---|
| | | *μM* | | |
| (+)-MK-801 | 0.015 | 0.009 | 0.024 | 0.038 |
| (−)-MK-801 | 0.35 | 0.32 | 0.038 | 0.17 |
| (+)-Ketamine | 16 | 1.6 | 1.1 | 1.5 |
| (±)-Norketamine | 51 | 8.7 | 5.6 | 7.5 |
| Dextromethorphan | 11 | 3.7 | 1.1 | 5.4 |
| Levomethorphan | 13 | 2.2 | 1.1 | 2.6 |
| Dextrorphan | 1.3 | 0.33 | 0.15 | 0.74 |
| Levorphanol | 1.8 | 1.2 | 0.58 | 2.1 |
| Phencyclidine | 0.82 | 0.16 | 0.16 | 0.22 |
| PCA | 19 | 3.9 | 1.6 | 1.7 |
| CNS-1102 | 0.13 | 0.068 | 0.087 | 0.14 |
| Amantadine | 130 | 70 | 35 | 38 |
| Remacimide | 81 | 35 | 92 | 63 |
| Pentamidine | 0.72 | 1.5 | 10 | 9.1 |
| 9-Aminoacridine | 7.8 | 7.5 | 29 | 38 |
| Memantine | 0.80 | 0.57 | 0.52 | 0.54 |
| Memantine–1 mM $Mg^{2+}$ | 13 | 10 | 1.6 | 1.8 |
| (±)-Ketamine | 0.33 | 0.31 | 0.51 | 0.83 |
| (±)-Ketamine–1 mM $Mg^{2+}$ | 5.4 | 5.08 | 1.2 | 2.9 |

CNS-1102, aptiganel; PCA, 1-phenylcyclohexylamine.



Downloaded from pharmrev.aspetjournals.org at ASPET Journals on December 27, 2024